Detalhe da pesquisa
1.
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
N Engl J Med
; 388(18): 1657-1667, 2023 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37133585
2.
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.
N Engl J Med
; 389(23): 2125-2139, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870968
3.
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Int J Cancer
; 154(5): 863-872, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37840339
4.
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
BMC Cancer
; 23(1): 470, 2023 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37217885
5.
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Eur Radiol
; 33(2): 1174-1184, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35976398
6.
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Int J Cancer
; 150(1): 112-123, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34431518
7.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35637412
8.
FIRE-9 - PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer.
BMC Cancer
; 22(1): 359, 2022 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35366831
9.
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Anticancer Drugs
; 31(8): 856-865, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32639280
10.
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT-ME-1 trial.
Int J Cancer
; 145(6): 1538-1546, 2019 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30801698
11.
Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial.
Blood
; 139(10): 1593-1597, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34932794
12.
CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.
Eur Radiol
; 28(12): 5284-5292, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29882070
13.
Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases.
Eur Radiol
; 28(11): 4839-4848, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29736851
14.
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Int J Cancer
; 140(8): 1918-1925, 2017 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28032641
15.
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Anticancer Drugs
; 28(7): 717-722, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28582279
16.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Lancet Oncol
; 17(10): 1426-1434, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27575024
17.
Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3.
Tumour Biol
; 36(4): 2631-40, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25472579
18.
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Anticancer Drugs
; 26(4): 371-8, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25514114
19.
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Acta Oncol
; 54(7): 993-1000, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25924969
20.
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(10): 1065-75, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25088940